Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Current Taxes (2023 - 2025)

Historic Current Taxes for Protalix BioTherapeutics (PLX) over the last 3 years, with Q3 2025 value amounting to $2.4 million.

  • Protalix BioTherapeutics' Current Taxes changed N/A to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year change of. This contributed to the annual value of $3.5 million for FY2024, which is 2086.23% up from last year.
  • Per Protalix BioTherapeutics' latest filing, its Current Taxes stood at $2.4 million for Q3 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Current Taxes peaked at $3.7 million during Q2 2025, and registered a low of $2.4 million during Q3 2025.
  • Moreover, its 3-year median value for Current Taxes was $3.5 million (2024), whereas its average is $3.2 million.
  • Over the last 5 years, Protalix BioTherapeutics' Current Taxes had its largest YoY gain of 2086.23% in 2024, and its largest YoY loss of 2086.23% in 2024.
  • Protalix BioTherapeutics' Current Taxes (Quarter) stood at $2.9 million in 2023, then rose by 20.86% to $3.5 million in 2024, then crashed by 31.39% to $2.4 million in 2025.
  • Its Current Taxes stands at $2.4 million for Q3 2025, versus $3.7 million for Q2 2025 and $3.5 million for Q1 2025.